Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
17.04
0.00 (0.00%)
At close: Sep 16, 2026, 4:00 PM EDT
17.03
-0.01 (-0.06%)
After-hours: Sep 16, 2026, 4:10 PM EDT
Theravance Biopharma Employees
Theravance Biopharma had 90 employees as of December 31, 2025. The number of employees decreased by 7 or -7.22% compared to the previous year.
Employees
90
Change (1Y)
-7
Growth (1Y)
-7.22%
Revenue / Employee
$1,159,011
Profits / Employee
$597,867
Market Cap
884.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 90 | -7 | -7.22% | 90 | 0 |
| Dec 31, 2024 | 97 | -2 | -2.02% | 97 | 0 |
| Dec 31, 2023 | 99 | -12 | -10.81% | 99 | 0 |
| Dec 31, 2022 | 111 | -48 | -30.19% | 111 | 0 |
| Dec 31, 2021 | 159 | -200 | -55.71% | 158 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Wave Life Sciences | 317 |
| Geron | 258 |
| Rigel Pharmaceuticals | 174 |
| Olema Pharmaceuticals | 150 |
| Solid Biosciences | 121 |
| Lexicon Pharmaceuticals | 81 |
| Candel Therapeutics | 55 |
TBPH News
- 22 days ago - Theravance Biopharma Proxy statement: Proxy filing - Filings
- 26 days ago - Theravance Biopharma Proxy statement: Proxy filing - Filings
- 5 weeks ago - Theravance Biopharma Proxy statement: Proxy filing - Filings
- 5 weeks ago - Theravance Biopharma reports Q2 revenue $20.7M, consensus $22.32M - TheFly
- 5 weeks ago - Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - Theravance Biopharma Earnings release: Q2 2026 - Filings
- 5 weeks ago - Theravance Biopharma Quarterly report: Q2 2026 - Filings
- 2 months ago - Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright - TheFly